Lecrolin, eye drops 20 mg/ml 10 ml

Lecroin is an anti-allergic drug, it stabilizes mast cell membranes. It prevents mast cells degranulation and release of histamine, bradykinin, leukotrienes (including slow-reacting substance) and other biologically active substances.

The drug is most effective when used prophylactically.

In allergic eye disease, the full clinical effect is achieved after a few days or weeks of treatment with the drug.

Pharmacokinetics

Absorption

When using eye drops absorption of sodium cromoglycate through the mucous membrane is negligible.

The systemic bioavailability is less than 0.1%.

Elimination

The T1/2 is 5-10 minutes.

Indications

Active ingredient

Composition

The eye drops are in the form of a clear solution, colorless or slightly yellowish.

1 ml of sodium cromoglycate 20 mg

Associated substances:

benzalkonium chloride,

dinatrium edetate,

How to take, the dosage

Adults and children are prescribed 1-2 drops of Lecroline in the lower conjunctival sac of the affected eye 4 times a day.

Interaction

There have been no negative symptoms of interaction of cromoglicic acid with other drugs.

The use of cromoglycic acid may reduce the need for use of ophthalmic drugs containing GCS.

Special Instructions

The use of Lecrolin eye drops in patients with allergic conjunctivitis reduces the need for GCS.

Lecroline is not indicated for the treatment of bacterial or viral conjunctivitis.

Lecrolin eye drops, packaged in a dropper bottle, contain the preservative benzalkonium chloride. Therefore, patients who wear contact lenses should remove them before using the drops and put them back in no earlier than 15 minutes after injection.

Cytotoxic, mutagenic and carcinogenic effects of cromoglicic acid have not been found in experimental studies.

Impact on ability to drive and operate machinery

The drug does not affect the patient’s ability to engage in potentially hazardous activities requiring increased attention and quick psychomotor reactions.

Contraindications

Side effects

Eye: short-term pain and local irritation are possible.

The benzalkonium chloride in the eye drops packed in dropper bottles is moderately cytotoxic and may cause superficial corneal epithelial damage; blepharitis, eyelid dermatitis, conjunctivitis and keratoconjunctivitis may also occur.

Overdose

In local application of the drug an overdose is unlikely. In experimental studies it has been shown that local and systemic toxicity of cromoglicic acid is very low.

Symptoms: nausea is possible.

Treatment: conducting symptomatic therapy.

Pregnancy use

The drug should be used with caution during pregnancy and lactation (breastfeeding) and only when the anticipated benefit to the mother outweighs the potential risk to the fetus or the infant.

Pediatric use

Contraindication: children under 4 years of age.

Similarities